Joshua Schimmer

Piper Jaffray Thinks It Might Be A Good Time For BioMarin To Sell Itself

Could Regenxbio Shares Have 320% Upside?

The Plot Thickens At Amgen; Piper Still Overweight

Could Regenxbio Shares Have 320% Upside?

The Plot Thickens At Amgen; Piper Still Overweight

Chimerix: Piper's 'Post-Blow-Up' Play

Piper Jaffray: Valeant's Business Could Be Broken Up In 2016

Chimerix: Piper's 'Post-Blow-Up' Play

Piper Jaffray: Valeant's Business Could Be Broken Up In 2016

Piper Jaffray: Akorn's Stock Will Be Delisted In 2016

Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016

Joshua Schimmer Recent News

Bluebuird Bio Crashes Nearly 30%: What's Next?

5 Biotechs That Can Win From Ophthalmology Innovation

Calls Of Note: The Research Moving Stocks Today

Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence…Even More Speculative Than Before'

Piper Jaffray Dishes On MannKind's Afrezza Data

Biogen Or Bluebird: Which Will Lead In SCD?

Piper Jaffray Names Chimerix Inc Top Ebola Play

Piper Jaffray Not Convinced MannKind's Afreeza Will Be Commercial Success

Shares of MannKind Plummet Prior to Drug Advisory Meeting

Piper Sees "Meaningful Utility" from GW Phamaceuticals CBD, Reiterates Overweight Rating

UPDATE: Piper Jaffray Initiates On Amgen On Series Of Bold Steps

UPDATE: Piper Jaffray Initiates on Alexion on High Revenue and EPS Growth Rates

UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On BMN-111 Outlook

UPDATE: Piper Jaffray Maintains Overweight On Vanda Pharmaceuticals On Hetlioz Outlook

Lazard Capital Markets Reiterates Buy on Vanda Pharmaceuticals on Good Entry Point

Leerink Swann Reiterates Incyte (INCY) Outperform Rating

Leerink Swann Reiterates Gilead Science (GILD) Outperform Rating